Aspirin Administration for Control of Tumor Millimetric Residual
New details about the role of proinflammatory pathways in the molecular pathogenesis of vestibular schwannoma have inspired the researchers to experiment aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of the tumor. Encouraging evidences have been reported in clinical studies. However, a double-blind, placebo-controlled, randomized trial is still missing and needed to ultimately address the efficacy of aspirin as a cytostatic on vestibular schwannoma and its correct posology. Second and even more ambitious target would be application of aspirin as a cytostatic for secondary prevention of tumor growth. In the personal experience, nine patients have undergone subtotal tumor resection and have been prescribed postoperative aspirin off-label with the purpose of avoiding recurrences. The maximum follow-up period has been 47 months, and only the first patient needed reoperation due to tumor regrowth; the remaining eight patients are being followed up and show stable tumors.
KeywordsVestibular schwannoma/emerging therapies Vestibular schwannoma/aspirin Vestibular schwannoma/NSAIDs Vestibular schwannoma/tumor residue